Invention Grant
US09358225B2 Method for treating neurodegeneration using a p38MAPK inhibitor
有权
使用p38MAPK抑制剂治疗神经变性的方法
- Patent Title: Method for treating neurodegeneration using a p38MAPK inhibitor
- Patent Title (中): 使用p38MAPK抑制剂治疗神经变性的方法
-
Application No.: US14215889Application Date: 2014-03-17
-
Publication No.: US09358225B2Publication Date: 2016-06-07
- Inventor: Paul K. Y. Wong
- Applicant: Bach Pharma, Inc.
- Applicant Address: US MA North Andover
- Assignee: Bach Pharma, Inc.
- Current Assignee: Bach Pharma, Inc.
- Current Assignee Address: US MA North Andover
- Agency: Occhiuti & Rohlicek LLP
- Main IPC: A61K31/10
- IPC: A61K31/10 ; A61K31/4184 ; A61K31/4188 ; A61K31/44 ; A61K31/4439

Abstract:
Ataxia-telangiectasia (A-T) is a progressive degenerative disorder that results in major neurological disability. In A-T patients, necropsy has revealed atrophy of all cerebellar cortical layers with extensive Purkinje and granular cell loss. We have previously identified an increase in phospho-p38MAPK levels, which was accompanied by downregulation of Bmi-1 and upregulation of p21, as key components of the mechanism causing defective proliferation of neural stem cells (NSCs) isolated from subventricular zone (SVZ) of Atm-null mice. Our results demonstrate that restoration of NSCs by pharmacologic inhibition of p38MAPK signaling has the potential to treat neurological defects of A-T. This study provides new insights into the therapeutic strategy targeting NSCs rather than replacing impaired neurons not only for A-T, but for other neurodegenerative disorders as well.
Public/Granted literature
- US20140303212A1 METHOD FOR TREATING NEURODEGENERATION USING A p38MAPK INHIBITOR Public/Granted day:2014-10-09
Information query